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Biomaterials used during surgery and wound treatment are of increasing importance in modern medical
care. In the present study we set out to evaluate the addition of thrombin-derived host defense peptides
to human acellular dermis (hAD, i.e. epiﬂex®). Antimicrobial activity of the functionalized hAD was
demonstrated using radial diffusion and viable count assays against Gram-negative Escherichia coli,
Pseudomonas aeruginosa and Gram-positive Staphylococcus aureus bacteria. Electron microscopy analyses
showed that peptide-mediated bacterial killing led to reduced hAD degradation. Furthermore, peptide-
functionalized hAD displayed endotoxin-binding activity in vitro, as evidenced by inhibition of NF-kB
activation in human monocytic cells (THP-1 cells) and a reduction of pro-inﬂammatory cytokine pro-
duction in whole blood in response to lipopolysaccharide stimulation. The dermal substitute retained its
anti-endotoxic activity after washing, compatible with results showing that the hAD bound a signiﬁcant
amount of peptide. Furthermore, bacteria-induced contact activation was inhibited by peptide addition
to the hAD. E. coli infected hAD, alone, or after treatment with the antiseptic substance poly-
hexamethylenebiguanide (PHMB), yielded NF-kB activation in THP-1 cells. The activation was abrogated
by peptide addition. Thus, thrombin-derived HDPs should be of interest in the further development of
new biomaterials with combined antimicrobial and anti-endotoxic functions for use in surgery and
wound treatment.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Over the past years, the use of biomaterial implants and tissue
transplants has increased in areas of orthopedics, cardiology,
ophthalmology, surgery, and dermatology, to name a few of many
uses [1]. Biomaterials may include polymers such as poly-
saccharides or collagen, silicon or nylon matrices, hyaluronic acid
and ester ﬁlms, ﬁbrin-based materials and hydrogels. Materials
implanted into the body of human or an animal must be sterile to
minimize risk for subsequent infection, and given bacterial pres-
ence, potential endotoxins should be controlled. Infection sensi-
tivity and risk for chronic infections are signiﬁcant biomaterial-Lund, Sweden. Tel.: þ46 46
setty).
Ltd. This is an open access articleassociated problems [1]. The exact mechanisms underlying
biomaterial-related infections have only been partly elucidated,
mainly with a current focus on adhesion and bioﬁlm formation.
However, in the initial contact with blood or tissues, various bio-
materials also induce an excessive inﬂammatory and coagulative
response [2e5]. In this perspective, novel biologically-oriented
strategies, providing coatings which comprise multiple features
such as control of inﬂammation and coagulation, and blocking of
bacteria and endotoxins should be of value.
Recently, scaffolds derived from xenogenic and allogenic
extracellular matrices have been developed for tissue engineering
applications including musculoskeletal, cardiovascular, urogenital
and integumentary structures [6]. These bioscaffolds are composed
of structural and functional proteins that are part of the native
mammalian extracellular matrix that provides structure, mechan-
ical properties, anchorage and communication sites for cells, factorsunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Over the past few years, allogenic human acellular dermis (hAD)
has been found to have several applications in reconstructive sur-
gery [8,9]. Concerns have been raised regarding acellular dermal
matrices as a separate risk factor for developing surgical-site
infection or inﬂammation [10,11]. However, current data describe
a relatively low rate of infection when sterile hAD is used [12,13].
Antimicrobial peptides (AMP) are important components of
innate immunity [14]. AMPs are short, cationic and amphipathic
peptides, displaying broad spectrum activity against various micro-
organisms, such as bacteria, fungi, andviruses [15,16]. AMPsmayalso
exert roles in modulating various immune responses [17e19],
motivating thedesignationhost defensepeptides (HDP). Researchon
novel aspects of the innate immune response activated during
infection and wounding has demonstrated that proteolytic cascades
generate several novel bioactive HDP with antimicrobial and anti-
inﬂammatory activities in vitro and in vivo [20e25]. In particular, C-
terminal peptides of human thrombin are generated in wounds and
ﬁbrin in response to infection and inﬂammation [20]. Considering
the functions of these HDPs, and their presence in the endogenous
“biomaterial”ﬁbrin,we aimed to develop an hADmatrix coatedwith
such thrombin-derivedHDPs and to explore its potential bactericidal
and anti-endotoxic characteristics. Therefore, we coated hAD with
the thrombinpeptidesGKY25 andGKY20 and evaluated their in vitro
activity against various bacterial strains characteristic for skin
wounds, their effects on lipopolysaccharide (LPS)-mediated inﬂam-
matory responses, and activation of coagulation-inducing kallikrein.
2. Materials and methods
2.1. Peptides
The peptides GKY20 (GKYGFYTHVFRLKKWIQKVI), GKY25 (GKYGFYTHVFRLKK-
WIQKVIDQFGE), and tetramethylrhodamine (TAMRA) labeled GKY25 were synthe-
sized by Biopeptide Co., San Diego, CA. The purity (95%) of these peptides was
conﬁrmed by mass spectral analysis (MALDI-ToF Voyager).
2.2. Microorganisms
The microorganisms used in the tests for antimicrobial activity were Escherichia
coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC
29213 obtained from the American Type Culture Collection.
2.3. Carrier material
Human cell-free (acellular) dermis allograft (epiﬂex®, DIZG, Deutsches Institut
für Zell- und Gewebeersatz gemeinnützige GmbH) was prepared as described pre-
viously [8]. A biopsy punch was used to fabricate discs with a diameter of 4 mm and
a thickness of 0.55 ± 0.25 mm to be used as a carrier material for peptides GKY25
and GKY20.
2.4. Disc coating
Peptides were solubilized in sterile water and stock solutions were prepared
with concentrations of 0.647,1.62 and 3.24mM. Each hAD-disc was coatedwith 10 ml
of peptide solution from an appropriate stock solution. After addition of the peptide
solution, discs were incubated in amoisture camber for 1 h at room temperature and
then freeze dried for 1 h. The ﬁnal amount of peptide per 4 mm hAD-disc were 6.5,
16.2, 32.4 nmol respectively. Polyhexamethylenebiguanide (PHMB) coated hAD-
discs were prepared by adding 10 ml of 0.1% PHMB (Cosmocil PG Polyhexanide,
ARCH UK biocides, United Kingdom) solution to the discs, followed by freeze drying.
2.5. Peptide release from discs
To measure the rate at which peptides were released from hAD, peptide-coated
discs were incubated in 100 ml of Tris buffer containing NaCl (10 mM Tris, pH 7.4,
0.15 M NaCl) at 37

C under shaking (500 rpm). Aliquots of 10 ml were taken after
1 min, 30 min, 6 h, and 24 h. Peptide activity was measured by a microbiological
assay (Radial Diffusion Assay, RDA) using E. coli ATCC 25922. A similar disc without
peptide served as control.
2.6. Radial diffusion assay
RDAwas performed as described previously [26]. Brieﬂy, bacteriawere grown to
mid-logarithmic phase in 10 ml of full-strength (3% w/v) tryptic soy broth (TSB)
(BectoneDickinson, Cockeysville, MD). The bacteria were washed once in 10 mM
Tris, pH 7.4 and subsequently, 4  106 bacterial colony forming units (cfu) wereadded to 15ml of the underlay agarose gel consisting of 0.03% (w/v) TSB,1% (w/v) low
electro endosmosis type (EEO) agarose (Sigma, St Louis MO) and 0.02% (v/v) Tween
20 (Sigma). The underlay was poured into a Ø 144 mm petri dish. After agarose had
solidiﬁed, 4 mm-diameter wells were punched and 6 ml of test sample was added to
eachwell. Plateswere incubated at 37

C for 3 h to allowdiffusion of the peptides. The
underlay gelwas then coveredwith 15ml ofmolten overlay (6% TSB and 1% Low-EEO
agarose in distilled H2O). Antibacterial activity of a peptide is visualized as a clear
zone around each well after 18e24 h of incubation at 37

C. The activities of the
peptides are presented as clear zone-well diameter (excluding the 4 mmwell).
2.7. Viable-count analysis
E. coli ATCC 25922 and S. aureus ATCC 29213 bacteria were grown to mid-
logarithmic phase in Todd-Hewitt (TH) medium (Becton and Dickinson, Maryland,
USA)andP. aeruginosaATCC27853bacteriawere grown inTHmediumovernight. The
bacteria were washed and diluted with 10 mM Tris, pH 7.4, containing 0.15 M NaCl.
Following this, bacteria (100 ml; 2  105 cfu/ml) were incubated at 37 C for 2 h, with
peptide-coated discs in 10mM Tris, 0.15MNaCl, with or without 20% human citrate-
plasma or 20% acute wound ﬂuid [27]. To quantify the bactericidal activity, serial
dilutions of the incubation mixtures were plated on TH agar, followed by incubation
at 37

C overnight and the number of cfu was determined. One hundred percent
survival was deﬁned as total survival of bacteria in the same buffer and under the
same condition in the absence of peptide. The discs were transferred to another TH
agar plate to determine the number of viable adherent bacteria on the disc.
2.8. NF-kB/AP-1 assay
NF-kB and AP-1 activation was assessed in THP1-Xblue™-CD14 reporter cells
(here denoted THP-1 cells) (InvivoGen, France) according to the company's in-
structions. In brief, cells were grown in RPMI 1640 with 10% (v/v) heat-inactivated
FBS, 1% AntieAnti (Invitrogen), 100 mg/ml G418, and 200 mg/ml of Zeocin. Cells
were centrifuged at 250  g for 5 min and re-suspended at 2  106 cells/ml in RPMI
supplemented with 10% heat-inactivated serum and 1% AntieAnti. Subsequently,
500 ml/well were placed on 24-well plates. Peptide-coated hAD-discs were incu-
bated with 20 ng of E. coli (0111:B4) LPS (SigmaeAldrich, USA; approximate 500.000
endotoxin units/mg) in 500 ml of RPMI medium at 37

C for 1 h. After incubation the
whole mixture including the disc was transferred to 500 ml of THP-1 cells and
incubated. After an 18e22 h incubation at 37 C and 5% CO2, activity was determined
in 20 ml of supernatant by using 180 ml QUANTI-Blue substrate (InvivoGen). Plates
were incubated at 37

C and the level of secreted embryonic alkaline phosphatase
(SEAP), an indicator of activation of transcription factors NF-kB and AP-1, was
measured after 1e2 h at OD 600 nm.
2.9. MTT assay
Sterile ﬁltered MTT (3-(4,5-dimethylthiazolyl)-2,5-diphenyl-tetrazolium bro-
mide; SigmaeAldrich) solution (5 mg/ml in PBS) was stored protected from light
at 20 C until use. 180 ml of THP1 cells were transferred to 96-well plates (Costar)
and 20 ml of the MTT solution was added to each well. Plates were incubated for 3 h
in CO2 at 37

C. After incubation the plate was centrifuged at 300  g for 10 min and
MTT containing medium was removed by aspiration. The blue formazan product
generated was dissolved by the addition of 100 ml of 100% DMSO (Applichem, Ger-
many) per well. The plates were then gently swirled for 30 min at room temperature
to dissolve the precipitate. The absorbance was measured at 550 nm, and results
given represent mean values from triplicate measurements.
2.10. Lactate dehydrogenase (LDH) assay
One hundred ml of each of the supernatants from the above experiment were
transferred to 96 well plates for determining LDH release. The LDH based TOX-7 kit
(SigmaeAldrich, St Louis, USA) was used for quantiﬁcation of LDH. Results given
represent mean values from triplicate measurements. Results are given as fractional
LDH release compared to the positive control consisting of 1% Triton X-100 yielding
100% LDH release.
2.11. Whole blood stimulation and cytokine analysis
Peptide-coated hAD-discs were incubated with 20 ng of E. coli LPS (Sigma) in
500 ml of RPMI medium at 37

C for 1 h. After incubation the whole mixture
including the disc was transferred to 500 ml of lepirudin-blood aliquoted in 24-well
plates. After 18e20 h incubation, plasma was collected and stored at 20 C. Cyto-
kine release was measured using BioSource CytoSet™ (Invitrogen) according to the
manufacturer's instructions.
2.12. Hemolysis assay
EDTA-bloodwas centrifuged at 800 g for 10min, and plasma and buffy coat were
removed. The erythrocytes were washed three times and re-suspended in 5% PBS,
pH 7.4. The cells were then incubated (with end-over-end rotation) for 1 h at 37

C in
the presence of peptide-coated discs or peptides alone at indicated concentrations.
Samples containing 2% Triton X-100 (SigmaeAldrich) served as positive control. The
samples were then centrifuged at 800 g for 10 min. The hemoglobin release was
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percentage of TritonX-100 induced hemolysis.
2.13. Chromogenic substrate assay
Bacteria were grown to mid-logarithmic phase in TH medium. The microor-
ganisms were then washed 3 times with 50 mM TriseHCl (pH 7.5), re-suspended,
and diluted to a ﬁnal concentration of 2  106 cfu/ml in 50 mM TriseHCl/50 mM
ZnCl2 buffer. A total of 100 ml of bacteria were incubated with peptide-coated discs
for 10 min before the addition of 100 ml human citrate plasma. Samples were
incubated for 30 min at 37

C with shaking. After centrifugation, pellets were
washed twice in 50mM Tris (pH 7.5), re-suspended in 100 ml 50mM TriseHCl/50 mM
ZnCl2 buffer containing 2 mM of the chromogenic substrate S-2302 (Chromogenix),Fig. 1. Peptide release proﬁle of hAD-discs coated with GKY20 and GKY25. (A) The rele
microbial activity in RDA. For determination of effects, E. coli ATCC 25922 (4  106 cfu) was
peptide collected at the indicated time points. The bar diagram in the upper panel indicates
released peptide after incubation at 37

C for 18e24 h (mean values ± SD are presented, n ¼
(B) For comparison with the antimicrobial activity of peptide-coated hAD-discs and peptid
shown. (C) Antimicrobial activity of peptides released from freshly prepared and 7-day-
values ± SD are presented, n ¼ 3).and incubated for 30e60 min at 37

C. The samples were centrifuged, and the
absorbance of the supernatants was measured at l ¼ 405 nm. No endogenous
proteolytic activity was measured when S-2303 was incubated with bacteria in the
absence of plasma.2.14. Data analysis
Values are shown as mean ± SD. For statistical evaluation of two experimental
groups, the ManneWhitney U-test was used. To compare more than two groups
One-Way or Two-Way ANOVA with Bonferoni post-test were used. All statistical
evaluations were performed using the GraphPad Prism software 6.0. with ns > 0.05,
*p  0.05, **0.01, ***p  0.001 and ****p  0.0001.ase of antimicrobial peptides from hAD-discs was determined by evaluating the anti-
inoculated in 0.1%TSB agarose gel. Each 4 mm-diameter well was loaded with 6 ml of
the zones of clearance obtained (in mm). These correspond to the inhibitory effect of
3). In the lower panel corresponding zones of clearance of one experiment are shown.
e alone, zones of clearance obtained with the indicated amount of peptide alone are
old (room temperature-preserved) peptide-coated discs determined by RDA (mean
Fig. 2. Antimicrobial effects of peptide-coated hAD-discs. (A) Antibacterial effects of peptide-coated discs against E. coli ATCC 25922 in viable count assays. 2  105 cfu/ml of
bacteria were incubated in 100 ml of 10 mM Tris, 0.15 M NaCl in the presence of hAD-discs with or without the indicated amount of peptides (mean values ± SD are presented, n ¼ 3).
(B) Visualization of bacteria adherent to peptide-coated hAD-discs. The discs were immersed in bacterial suspensions (2  105 cfu/ml) and incubated for 2 h at 37 C. The discs were
transferred to fresh TH agar plates for determining viable bacterial colonies (image of one representative experiment is shown, n ¼ 3).
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3.1. Antimicrobial peptide release proﬁle of human acellular dermis
coated with thrombin peptides
As mentioned above, GKY20 and GKY25, two C-terminal HDPs
derived from human thrombin, have broad antimicrobial and
immunomodulatory activities [25]. In order to determine antimi-
crobial effects of functionalized material, hAD-discs coated withFig. 3. Peptide-coated human acellular dermis discs inhibit bacterial growth. Antibacter
and S. aureus ATCC 29213 in viable count assays. 2  105 cfu/ml of bacteria were incubated in
The experiment was performed in 10 mM Tris, pH 7.4, 0.15 M NaCl. Bacteria incubated w
appropriate dilutions of the bacterial solutions on TH agar plates. Plates were incubated at
shown, n ¼ 3).increasing amounts of GKY20 and GKY25 were incubated in 10 mM
Tris, 0.15 M NaCl, pH 7.4. At different time points (1 min-24 h),
aliquots of the disc supernatant were collected. The release of active
peptide was indirectly assessed by determining the antimicrobial
activity of the samples using RDA against E. coli (Fig. 1A. As
observed, the peptides were rapidly released. After 24 h of incu-
bation, GKY20 released from hAD showed larger inhibition zones
than those observed for GKY25. The antimicrobial activity was dose
dependent and a minimum of 6.5 nmol of peptide (correspondingial effects of the peptide-coated discs on E. coli ATCC 25922, P. aeruginosa ATCC 27853,
100 ml in the presence of hAD-discs with or without 32.4 nmol of the indicated peptide.
ithout hAD-disc were used as control. Bacterial growth was determined by plating
37

C over night and cfu were determined (image of one representative experiment is
G. Kasetty et al. / Biomaterials 53 (2015) 415e425 419to 20 mg GKY25) released during 24 h was required for detecting
any antibacterial effects in the system used. For comparison, pep-
tides alone were also tested for their antimicrobial activity (Fig. 1B).
The antimicrobial activity at 0.65,16.2 and 32.4 nmol was higher for
peptides alone when compared to samples containing peptide
released from impregnated discs (compare Fig. 1A and B). This
difference suggested a certain amount of peptide binding to the
hAD-discs. Therefore, in a separate experiment, the binding and
release of GKY25 to hAD was assessed using discs impregnated
with 32.4 nmol peptide, of which 2% was labeled with the ﬂuo-
rescent label TAMRA. TAMRA-GKY25 has similar characteristics as
the endogenous GKY25 with respect to antimicrobial and anti-
inﬂammatory activity [20] [Kalle et al., manuscript in prepara-
tion]. Analysis of both ﬂuorescent and unlabeled peptide remaining
on the discs after repeated washings in buffer, demonstrated that
approximately 30e40% of the peptide amount was released after
6 h. Tracking of TAMRA-GKY25 demonstrated an initial peptide
release of about 20e25% after 30 min, followed by a “leakage
phase” during the 6 h wash period (Supplementary Fig. 1). The
above observed reduction of antimicrobial effects of material eluted
from the hAD (Fig. 1A), is thus compatible with peptide binding to
the hAD. Finally, In order to test the stability of the peptides on hAD,
the antimicrobial activity of coated discs, stored for 7 days at room
temperature, was compared with the activity of newly prepared
discs (Fig. 1C). Notably, there was no signiﬁcant difference in the
peptide release proﬁle, as demonstrated by similar antimicrobial
activity against E. coli in RDA.
3.2. Antibacterial effects of peptide-coated human acellular dermis
To investigate the antimicrobial efﬁcacy, the peptide-coated
hAD-discs were incubated with E. coli in physiological bufferFig. 4. Antimicrobial activities at physiological conditions. E. coli ATCC 25922 bacteria wer
the same buffer containing 20% human plasma or 20% acute wound ﬂuid. To quantify bacter
followed by incubation over night at 37

C and the number of cfu was determined (imageconditions for 2 h. In concordance with the above results, only discs
coated with GKY20 or GKY25 displayed antimicrobial activity
(Fig. 2A). With 16.2 and 32.4 nmol peptide added, both peptides
yielded complete killing of E. coli bacteria. Simultaneously, as pre-
sented in Fig. 2B, the presence of remaining viable adherent bac-
teria on the discs was investigated by placing the discs on sterile TH
agar plates. The control disc was surrounded by bacterial growth. In
accordance with the RDA and viable count data shown above, the
two peptides inhibited bacterial growth on the discs, particularly at
doses at or above 16.2 nmol per disc.
P. aeruginosa and S. aureus are frequently isolated from patients
suffering from infected burns as well as chronic wounds [28].
Therefore, using viable count assays as above, the antimicrobial
activity of peptide-coated discs (32.4 nmol peptide/disc) was
determined against these pathogens and comparedwith the results
on E. coli bacteria (Fig. 3). Both peptides completely eradicated the
two Gram-negative bacterial strains E. coli and P. aeruginosa. A large
proportion of the Gram-positive S. aureus bacteria population was
killed by GKY25 and GKY20 (Fig. 3). Since it has been shown that
AMPs may be inhibited in plasma [29], we also tested the activity of
the peptide-coated discs in plasma as well as acute wound ﬂuid.
The results showed that the peptides largely retained their anti-
microbial activity in these environments (Fig. 4).
3.3. Peptides protect human acellular dermis from degradation by
bacteria
Scanning electron microcopy (SEM) images of the hAD-surface
with and without peptide-coating, incubated with bacteria for 2
and 24 h are shown in Fig. 5. As seen in the control discs, the surface
of the hAD is covered with P. aeruginosa (Fig. 5A) and S. aureus
(Fig. 5B), and degradation of collagen ﬁbers can be observed (lowere incubated with peptide-coated discs (32.4 nmol) in 10 mM Tris pH 7.4, 0.15 M NaCl or
icidal activity appropriate dilutions of reaction mixtures were plated on TH broth agar
of one representative experiment is shown, n ¼ 3).
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signiﬁcant bacterial inhibition at the two time points. Destruction
of the collagen ﬁbers was not observed.
3.4. Endotoxin-blocking effects of peptide-coated human acellular
dermis
In addition to killing microbes directly, HDPs derived from
thrombin have been shown to inhibit pro-inﬂammatory responsesFig. 5. Visualization of antimicrobial effects on the surface of human acellular dermis. (
(A) P. aeruginosa and (B) S. aureus. Upper panel shows extensive killing of bacteria on the sur
degradation, which is prevented on peptide-coated discs. (Control: hAD alone, incubated foas well as excessive coagulation [30]. Thus we evaluated the
immunomodulatory activity of peptide impregnated hAD in vitro
using THP1-XBlue™-CD14 cells. To exclude the possibility of an LPS
contamination of the hAD, an LAL test (limulus amoebocyte lysate
test) was performed to detect the amount of endotoxin present. No
detectable levels of bacterial endotoxins were found in the hAD
material (data not shown). Thus, ﬁrst, effects of peptides on LPS-
induced NF-kB and AP-1 activation in THP1-XBlue™-CD14 cells
weremeasured. Cells were incubatedwith E. coli LPS (10 ng/ml) andA) SEM images of hAD-discs after incubation with bacteria for 2 and 24 h, respectively.
face of the hAD-disc after a 24 h incubation time. Lower panels illustrate collagen ﬁber
r 24 h).
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bation,NF-kBandAP-1 activationwas assessed. The results in Fig. 6A
show that discs coatedwith the two peptides blocked theNF-kB and
AP-1 activation in a dose-dependent manner. However, complete
blocking was only observed for hAD-discs coated with 32.4 nmol of
peptide. To determine whether hAD itself could activate the cells,
different batches of hAD-discs alone (3 discs from each batch), were
incubated with THP-1 cells for 18 h and the NF-kB and AP-1 activa-
tionwas studied. Aminor, and variable activationwas observedwith
different hAD batches (Fig. 6B), probably reﬂecting biological vari-
ability and material differences, as previously described for other
acellular dermal matrices [31]. Further, as the results in Fig. 1A and
Supplementary Fig.1A and B indicated a certain degree of binding of
the peptides to hAD, we undertook to investigate whether peptide-
coated hAD still retained the anti-endotoxin effects after three
repeatedwashing stepswith buffer (10mMTris, 0.15MNaCl, pH7.4)
as well as more extensive washing for 6 h (Supplementary Fig. 1C).
Following washing, the discs were incubated with E. coli LPS (10 ng/
ml) and later transferred to THP-1 cells to assess NF-kB and AP-1
activation. As seen, the washed discs retained their anti-endotoxin
activity in these experimental setup (Fig. 6C, Supplementary Fig.1C).
Next, we also determined if the peptide-impregnated hAD-discs
could inhibit the LPS-induced production of pro-inﬂammatory cy-
tokines in whole blood. Human blood was stimulated with 10 ng/
ml E. coli LPS in the absence and presence of hAD-discs with or
without peptides. In accordance with previous data, both peptide-
coated discs signiﬁcantly inhibited the production of the proin-
ﬂammatory cytokines TNF-a, IL12p40, but also the anti-
inﬂammatory cytokine IL-10 (Fig. 6D). Many antimicrobial pep-
tides may also permeabilize human cells in vitro [32,33], effects
which often are abrogated after addition of plasma or blood [15].Fig. 6. Anti-inﬂammatory effects of peptide-coated hAD-discs. (A) THP1-XBlue™-CD14 c
bar diagram indicates the activation of NF-kB as determined by measuring the production
incubated with discs from different batches of human acellular dermis and the NF-kB activ
cells were stimulated with 10 ng/ml E. coli LPS in presence of washed peptide-coated disc
washed 3 times for 10 min each in 1 ml Tris, 0.15 M NaCl, pH 7.4 and subsequently incubated
activation of NF-kB (mean values ± SD are presented, n ¼ 3). (D) Human blood was stimulat
with peptide). The levels of TNF-a, IL-12p40, and IL-10 are presented as percentage in relaTherefore, we evaluated the cytocompatibility of these peptides
with erythrocytes and the human monocyte THP-1 cell line. As
presented in Fig. 7A a dose-dependent permeation effect on
erythrocytes was observed. Compatible with previous reports, the
peptide GKY20 was less hemolytic [25]. Importantly, when the
same amount of peptide was incorporated into hAD-discs, no he-
molysis was observed (Fig. 7A), compatible with the observed
scavenging of the peptides by the hADmatrix, reducing the amount
of free peptide (Fig. 1A, Supplementary Fig. 1A and C). Further,
potential toxicity of peptides towards the human monocytic cell
line THP-1 was evaluated using MTT and LDH assays (Fig. 7B and C)
in the various indicated conditions. No peptide-mediated toxicity
was observed after an incubation time of 18e20 h (Fig. 7B, C). In
summary, these results suggest that, in line with previous reports
[20,25,30], both GKY20 and GKY25 inhibited LPS-induced cellular
responses without signiﬁcantly affecting the cell viability.
3.5. Effect of peptide-coated human acellular dermis on contact
activation
Previously, it was shown that GKY25 impairs the intrinsic
pathway of coagulation in both human and murine plasma [30].
The contact system is initiated on bacterial membranes or nega-
tively charged surfaces such as kaolin. This involves activation of
FXII, which in turn activates plasma kallikrein (PK) and leads to FXI
activation [34]. Depending on the type of surface, biomaterials may
also induce this activation of the coagulation system [35]. Therefore
we measured the PK activation at the surface of hAD alone and in
combination with bacteria (P. aeruginosa) in order to mimic the
conditions of a bacterial infection at an implantation site. As shown
in Fig. 8, hAD, when in contact with human plasma activated theells were stimulated with 10 ng/ml E. coli LPS in presence of peptide-coated discs. The
of SEAP (mean values ± SD are presented, n ¼ 3). (B) THP1-XBlue™-CD14 cells were
ation was evaluated (mean values ± SD are presented, n ¼ 3). (C) THP1-XBlue™-CD14
s and the NF-kB activation was evaluated. The peptide-coated discs (32.4 nmol) were
with E. coli LPS for 1 h. The whole mixture was added to THP1 cells to determine the %
ed for 18 h with 10 ng/ml E. coli LPS alone, or in presence of hAD-discs (alone or coated
tion to LPS alone which is deﬁned as 100% (mean values ± SD are presented, n ¼ 5).
Fig. 7. Effects of peptide-coated discs on cell viability. (A) Hemolytic effects were investigated by incubating erythrocytes with peptides alone (Peptide) or peptide-coated hAD-
discs (mean values ± SD are presented, n ¼ 3). (B) The percentage of viable cells was quantiﬁed with an MTT assay (mean values ± SD are presented, n ¼ 3). (C) LDH release in
supernatants of THP1-XBlue™-CD14 cells was determined. Values are presented in relation to the positive control (deﬁned as 100%) (mean values ± SD are presented, n ¼ 4).
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higher when compared to hAD alone. The decrease in PK activity
was found to occur in a dose-dependent manner in the peptide-
coated hAD samples (Fig. 8). These results thus demonstrated
that exposure to hAD alone could induce activation of the coagu-
lation system, that the initiation was increased in presence of
bacteria, and that the two HDPs inhibited this activation.Fig. 8. Effects on contact activation of peptide impregnated hAD-discs in absence
and presence of bacteria. hAD-discs with or without peptide were incubated with
P. aeruginosa ATCC 27853. After 10 min, human plasma was added and incubated for
additional 30 min. The plasma was then removed by centrifugation and the pelleted
bacteria were washed and re-suspended in substrate buffer. After 15e30 min of in-
cubation, plasma kallikrein activity was measured in a substrate assay. Data are pre-
sented as percentage activity compared to the control (mean values ± SD, n ¼ 2).3.6. Effects of GKY25 in combination with PHMB
Antiseptics such as polyhexamethylenebiguanide (PHMB) are
commonly used in wound care. We hypothesized that PHMB, by
killing bacteria, may lead to the release of proinﬂammatory endo-
toxins. In order to investigate whether GKY25 could block these
endotoxins, hAD discs coated with GKY25, PHMB or combinations
thereof were incubated with E. coli bacteria for 2 h. Following in-
cubation, cfu were determined. More than 99% of the bacteria were
killed by PHMB, GKY25, and PHMB with GKY25 (data not shown).
Subsequently, the bacterial suspension including the discs was
transferred to THP-1 cells to assess NF-kB and AP-1 activation. As
demonstrated in Fig. 9 (upper panel), only hAD discs coated with
GKY25 alone or in combinationwith PHMB blocked NF-kB and AP-1
activation. LDH and MTT assays (middle and lower panel), showed
that the substances alone or in combination had minor or no
permeation effect. These results demonstrate that GKY25 addition
to PHMB inhibits the proinﬂammatory actions of endotoxins
released after subjecting bacteria to the antiseptic.4. Discussion
Despite several advances in prophylactic measures, infections
still remain a signiﬁcant complication related to biomaterials [1]. A
technically successful operation is no guarantee against
biomaterial-associated infections. It is estimated that during sur-
gery in a standard operating theater environment, airborne bacte-
rial wound contamination occurs at approximately 270 bacteria/
cm2 [36], and hence, most likely, sterile implant surgery is not
possible. Although recent advancements in airﬂow and preventa-
tive techniques, particularly used in specialized surgery settings,
Fig. 9. Anti-inﬂammatory effects of GKY25 in combination with PHMB. Discs
coated with 32.4 nmol GKY25, 0.1% PHMB, or combinations thereof were incubated
with E. coli (100 ml; 2  106 cfu/ml) for 2 h. The bacterial suspension including the discs
were transferred to THP1-XBlue™-cells to assess NF-kB and AP-1 activation. The bar
diagram in the upper panel indicates % activation of NF-kB as determined by
measuring the production of SEAP (secreted embryonic alkaline phosphatase).
Simultaneously, LDH release and cell viability using an MTT assay was determined.
(mean values ± SD are presented, n ¼ 3).
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operative bacterial load, albeit reduced, is still a cause of infections
worldwide. It is also notable that bacteria may be released into the
wound from deeper layers in the skin [37,38]. In order to meet this
problem, various antimicrobial coatings have been developed,
particularly for use in revision surgery, and involving antibiotics
released from implant coatings, or device ﬁxationmaterials, such as
antibiotic-loaded bone cements [39]. In other instances silver-
impregnated coatings, or coatings that kill bacteria immediately
upon adhesion to the coating are used for prevention of implant
infection [1]. With respect to inﬂammation, anti-inﬂammatorysurfaces are of high interest [2,4]. For example, Nilsson and col-
leagues showed that a factor H-binding peptide; and an ADP-
degrading enzyme; using a PEG linker on both material and
cellular surfaces inhibited complement attack [40]. Thierry et al.
used an approach toward biomimetic surfaces based on the cova-
lent immobilization of a carboxylate terminated PEGylated hya-
luronan (HA-PEG) onto plasma functionalized NiTi alloy surfaces
[41]. In other developments, synthetic polymer brushes are used
as temaplates for further bioengineering of surfaces with enhaced
biocompatibility [42].
In this perspective, the concept presented here, based on a
thrombin-derived endogenous peptide, found in ﬁbrin and
released in wounds, represents a novel means of providing a new
biological and endogenous antimicrobial functionality to an acel-
lular dermal biomaterial. Previous studies on the two prototypic
thrombin C-terminal peptides GKY20 and GKY25 demonstrated
that these peptides exert a broad spectrum of antimicrobial and
immunomodulatory activities that include inhibition of production
of multiple pro-inﬂammatory cytokines, reduction of vascular
leakage, blocking of contact activation and tissue factor-mediated
pathways of the coagulation system during LPS-induced experi-
mental shock and in animal models of P. aeruginosa sepsis
[20,25,30]. For both LPS-induced shock and P. aeruginosa-induced
sepsis, regulation of excessive cytokine levels is regarded as a
relevant therapeutic target, and it is therefore notable that the
peptides signiﬁcantly dampen the pro-inﬂammatory cytokine
response both in vitro and in vivo.
From the perspective of biomaterials however, the impact on
cellular responses such as vasodilation, chemotaxis, and (impor-
tantly and speciﬁcally), local activation of the coagulation and
complement systems may also play critical roles in modulating
biocompatibility [2e5,35,43e46]. The inﬂammatory responses
caused by implanted materials could be major factors leading to
complications or degradation [35,47,48]. It is of note, that also
endogenous biomaterials, such as dermal substitutes, although
considered less proinﬂammatory, may exert some activating effects
on monocytes in vitro [31]. In this perspective, the results in this
present work indicate that coating with thrombin-derived peptides
adds host defense functions to the human acellular dermis per se.
Thus, in addition to a bactericidal effect, coating adds functional-
ities such as LPS-scavenging and reduction of bacteria-induced
contact activation to hAD. In both cases, these effects could lead
to advantageous inhibition of local inﬂammatory responses.
Furthermore, the ﬁnding that the peptides were adsorbed by the
hAD indicates that the cationic and amphipathic peptide may
interact with the dermal matrix, consisting of collagen, hyaluronic
acid, and other matrix components [49]. For example, peptide in-
teractions with carboxyl-groups of hyaluronic acid, or matrix-
derived heparan sulfate are likely to occur and may underlie the
observed peptide-hAD binding. From the perspective of pharma-
codynamics, analyses on peptide release, stability, as well as effects
of serum components should be of importance for further thera-
peutic developments. For example, given the binding of the peptide
to hAD, the relative contribution of bound and released peptide to
the observed effects of the hAD matrix in vitro should be deter-
mined in more detail. Nevertheless, it is notable that peptide-
coated and washed functionalised hAD blocked LPS responses in
a serum environment.
Finally, the observation that the peptide blocked the proin-
ﬂammatory effects of PHMB-killed E. coli is particularly relevant.
Apart from extending the concept of endotoxin-scavenging to in-
hibition of responses to whole E. coli bacteria, the results imply that
the strong antimicrobial potency of PHMB could be complemented
with the anti-inﬂammatory effects of GKY25 in various therapeutic
approaches.
G. Kasetty et al. / Biomaterials 53 (2015) 415e425424Upon initial contact with blood or tissues, biomaterials may
induce a dysfunctional immune response at the local level, which,
as in systemic sepsis, may cause a dysfunctional host defense. If so,
this reasoning implicates that the surroundings of a biomaterial
may be infection-prone. In the case of experimental (systemic)
sepsis, the thrombin peptides reduced coagulation factor con-
sumption, and normalized coagulation and cytokine responses.
With this as background, creating a situation in which proin-
ﬂammatory mediators are controlled locally with immunomodu-
latory peptide coatings, enabling a preserved immune and
coagulation response could be a new and attractive strategy for
enhancing infection control for a given biomaterial. Clearly, future
experiments using in vivo biomaterial models addressing not only
antibacterial and anti-inﬂammatory effects on a wider range of
gram-negative and gram-positive bacteria, but also pharmacody-
namic aspects such as release, stability, and metabolism, are
needed in order to explore potential therapeutic uses of such
peptide-coated biomaterials.
5. Conclusions
Coating of a hAD with endogenous host defense peptides of
thrombin adds antimicrobial and endotoxin-blocking properties to
the biomaterial, as demonstrated using RDA, viable count assays,
and SEM for analyses of antimicrobial activity, in combination with
assays for LPS-binding activity, inhibition of NF-kB activation in
monocytes, and reduction of contact activation in plasma. Of
importance is the ﬁnding that the proinﬂammatory action of
PHMB-treated bacteria is blocked using such peptide-
functionalized hAD. Taken together, coatings with thrombin-
derived HDPs constitute an interesting strategy for the develop-
ment of improved biomaterials with combined antimicrobial and
anti-inﬂammatory functions. The present results based on in vitro
studies, open up new possibilities to modulate unwanted bioma-
terial- and/or bacteria-induced reactions also in vivo.
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